Skye Bioscience Inc (SKYE)

[AntonChigurh]

Are you one of those Ban the Fed guys?

I'm not a macro guy. But 20 million is still 20 million. NMUS has been spending about a one million on research and licenses, so 20 would go a long way. [t][/t]



With that 20m, they could do different things. All of those involve one of their candidates completing a Phase 2 trial in 2018.

Before Zynerba's readouts, the Street was giving them a 250m market cap with 60ish million cash. Imagine what they would of been valued at with Positive results!

I don't know where along the development path Nemus will find a partner for one of their indications, if at all. However, the further Nemus goes down the road of approval with a drug(s), the market will price in a % of potential revenues from the drug(s). If required, I think future financings will be done at a higher valuation and be less dilutive than in the past than the most recent one.

If the most recent financing was to fall though and not complete, I think NMUS will be able to raise capital to continue operations and research. Since the company has completed previous raises diligently, and I would assume do the same in the future. One of the many advantages of owning shares in a company run by Good operators. 5-10m gets them into Phase 2 with something IMO.

Even though People got burned with ZYNE, the interest is there for the space and the Scoreboard won't lie.

You are right that ElSohly and UM were involved with another pharma about something that sounds similar to NB1222 and it didn't go through. I remember an article was posted awhile back. I don't think enough information is available to be able to form a strong opinion about why things never moved forward. It was a long time ago too. Post anything you have about it.

How can you say that there is no data showing the improved pharmacokinetics of the THC-VHS prodrug (NB1222)?

http://www.sciencedirect.com/science/article/pii/009130579390194X
http://europepmc.org/abstract/med/8897084

There is some on the NMUS website too.

The current patent is here: https://www.google.com/patents/US8809261

I'm not sure what the formulation would be with a transmucosal patch. I guess it would depend on what indication it is. But seems like down the list of things considering NB1222 (suppository) and NB1111 (eye drops-->contact lense)

'wouldn't the absorption as a suppository be too quick?' No, see the above research. I think NMUS is in the proccess of answering your question. NMUS will prove it on the field anyway. You can say whatever you want, but the scoreboard doesn't lie.